Introduction
============

Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder characterized by a combination of various degrees of parkinsonism, cerebellar ataxia and autonomic dysfunction ([@b1-mmr-17-01-0852]). At present, there are no established biomarkers of MSA and so the clinical diagnosis of MSA is dependent on the assessment of clinical symptoms, thus misdiagnoses are frequent ([@b2-mmr-17-01-0852]). The characteristic pathological hallmark of MSA is the accumulation of α-synuclein positive glial cytoplasmic inclusions in oligodendrocytes ([@b3-mmr-17-01-0852]). The pathogenesis of MSA remains unclear, although it has been reported that α-synuclein accumulation serves a key role in neurodegeneration ([@b3-mmr-17-01-0852],[@b4-mmr-17-01-0852]).

microRNA (miRNA) are short RNA molecules that function as post-transcriptional regulators that bind to complementary sequences on target mRNA transcripts, typically resulting in translational repression or target degradation and gene silencing ([@b5-mmr-17-01-0852]). Previous studies have demonstrated that the dysregulation of miRNA serves an important role in a number of neurological disorders, including Alzheimer\'s disease, Parkinson\'s disease (PD) ([@b6-mmr-17-01-0852]) and amyotrophic lateral sclerosis ([@b7-mmr-17-01-0852]). However, the miRNA profile of patients with MSA remains to be fully investigated.

Increased serum levels of insulin like growth factor (IGF)-1 have been reported in patients with MSA ([@b8-mmr-17-01-0852],[@b9-mmr-17-01-0852]). Since IGF-1 signaling has been revealed to be regulated by several miRNAs ([@b10-mmr-17-01-0852],[@b11-mmr-17-01-0852]), it may be hypothesized that miRNAs and IGF-1 contribute to the pathogenesis of MSA.

In the present study, the expression of serum miRNAs and IGF-1 was investigated in patients with MSA, in order to identify potential biomarkers and clarify the pathogenesis of MSA.

Materials and methods
=====================

### Patients and samples

A total of 10 patients with MSA (7 males and 3 females; mean age, 64±6.9 years; range, 49--75 years) and 6 age- and sex-matched healthy controls (caregivers of the MSA patients without MSA; 4 males and 2 females; mean age, 64±2.9; range, 58--66 years) were recruited for the present study between January and December 2013, from the Department of Neurology, Kagawa University Hospital. All of the patients with MSA were diagnosed according to the 2008 consensus statement on the diagnosis of MSA: Definite, 1 patient; probable, 4 patients; possible, 5 patients ([@b12-mmr-17-01-0852]). Five of the 10 patients had MSA of the parkinsonian form (MSA-P), and the other 5 patients had MSA of the cerebellar form (MSA-C). The mean duration of the illness was 5.5±2.8 years ([Table I](#tI-mmr-17-01-0852){ref-type="table"}). Blood samples were harvested upon recruitment and processed for serum isolation within 2 h following withdrawal. Whole blood was centrifuged at 1,500 × g for 15 min at 4°C. Each serum sample was divided into aliquots and stored at −80°C until analysis. Informed consent was obtained from all of the participants and the present study was approved by the Ethics Committee of Kagawa University (Kagawa, Japan).

### RNA isolation

Total RNA was extracted from the serum samples using an miRNeasy Mini kit (Qiagen, Inc., Valencia, CA, USA) according to the manufacturer\'s instructions. All RNA samples used in the present study exhibited A260/280 ratios between 2.0 and 2.1. The integrity of RNA was determined using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Inc., Waltham, MA, USA). The quality of total RNA was determined using the RNA Nano 6000 chips from the Agilent 2100 Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA, USA) according to the manufacturer\'s protocol, and all RNA samples used for the microarray analyses had RNA Integrity Number values \>8.2. Briefly, total RNA from all serum samples was heated at 70°C for 2 min and incubated on ice for 5 min. Subsequently, samples (1 µl) were loaded into each lane on the RNA Nano 6000 chips, and the bands of 18S (arrow) and 28S ribosomal RNA (arrowhead) in the gel were detected using the Agilent 2100 Bioanalyzer ([Fig. 1A](#f1-mmr-17-01-0852){ref-type="fig"}). These RNA samples were stored at −80°C.

### miRNA arrays

Total RNA was labeled with Hy3 dye using an miRCURY LNA microRNA Array Hi-Power Labeling kit (Exiqon A/S, Vedbæk, Denmark). Total RNA (2 µg) was incubated with a spike of 30 min at 37°C and then at 95°C for 5 min. Hy3 dye and Hi-Power Labeling enzyme were then added to each sample. The enzyme was then heat-inactivated at 16°C for 1 h and at 65°C for 15 min, protected from light. The samples were loaded onto the arrays by capillary force using 3D-Gene miRNA oligo chips (version 17; Toray Industries, Inc., Tokyo, Japan). The chips enabled the examination of the expression of 679 miRNAs printed in duplicate spots.

The arrays were incubated at 32°C for 16 h, then briefly washed in a 30°C wash buffer solution \[0.5X saline-sodium citrate (SSC), 0.1% SDS\], rinsed in wash buffer solution (0.2X SSC, 0.1% SDS) and then washed again in another buffer solution (0.05X SSC), according to the manufacturer\'s instructions (Toray Industries, Inc.). The arrays were centrifuged for 1 min at 600 × g at room temperature for drying, followed by immediate scanning using a 3D-Gene 3000 miRNA microarray scanner (Toray Industries, Inc.). It was calculated that the relative expression level of each miRNA by comparing the average signal intensities of the valid spots with their mean value throughout the microarray experiments, following normalization to their adjusted median values.

### Quantification of miRNA

Isolation of RNA was performed using a miRNeasy serum/plasma kit adding spike in control cel-miR-39 (Qiagen, Inc.), according to the manufacturer\'s protocol. cDNA was individually synthesized for each target miRNA using miRNA Reverse Transcription kit (Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocol. The detection of miRNA expression was performed by reverse transcription-quantitative polymerase chain reaction (RT-qPCR), using TaqMan miRNA Assays and TaqMan Universal Master MixII (Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocol. Thermocycling conditions were as follows: Initial denaturation at 95°C for 10 min, followed by 40 cycles at 95°C for 15 sec and at 60°C for 60 sec. The relative expression levels of miRNA were calculated using the comparative Cq method ([@b13-mmr-17-01-0852]) and normalized to cel-miR-39 expression. Experiments were performed in triplicate.

### Heatmap

A heatmap was created using R software version 3.2.3 (<https://www.R-project.org>) in which the expression levels of miRNAs from each of the 10 MSA patients and 6 healthy controls were represented using unsupervised hierarchical clustering Brunner-Munzel analysis. The heatmap was color-coded according to the log2-transformed expression levels. The center level of the color code is set as the median value over all of the values used in the heatmap. White color represented mean values, red indicated an increase and blue represented a decrease in expression.

### Measurement of IGF-1

Serum IGF-1 levels were measured by Shikoku Chuken (Ayagawa, Japan) using an immunoradiometric assay.

### Statistical analysis

Data are expressed as the mean ± standard deviation. The statistical significance of the differences between groups was assessed using unpaired Student\'s t-test. P\<0.05 was considered to indicate a statistically significant difference. Statistical analysis was performed using SPSS software version 23.0 (IBM Corp., Armonk, NY, USA).

Results
=======

### Identification of differentially expressed plasma miRNA in the patients with MSA and healthy controls

The miRNA expression levels in serum obtained from the patients with MSA and healthy controls were compared. The custom microarray platform identified 50 miRNAs that were upregulated and 17 miRNAs that were downregulated in the serum of the patients with MSA ([Table II](#tII-mmr-17-01-0852){ref-type="table"}). As shown in [Fig. 1B](#f1-mmr-17-01-0852){ref-type="fig"}, the representative upregulated miRNAs were: miR-16 (spot no. 1), miR-223 (spot no. 2), miR-25 (spot no. 3), let-7c (spot no. 4), miR-17 (spot no. 5), let-7d (spot no. 6), let-7i (spot no. 7), let-7b (spot no. 8), miR-24 (spot no. 9), let-7a (spot no. 10) and miR-20a (spot no. 11). An unsupervised hierarchical clustering analysis using a Brunner-Munzel test revealed that the patients with MSA clustered separately from the healthy control group ([Fig. 2](#f2-mmr-17-01-0852){ref-type="fig"}).

### Identification of differentially expressed plasma miRNA in the MSA-P and MSA-C patients

The miRNA expression levels in serum obtained from the MSA-P and MSA-C patients were then compared. This analysis identified that 22 miRNAs were upregulated and 17 miRNAs were downregulated in the serum of the patients with MSA-P ([Table III](#tIII-mmr-17-01-0852){ref-type="table"}). An unsupervised hierarchical clustering analysis using a Brunner-Munzel test demonstrated that the MSA-P patients clustered separately from the MSA-C patients ([Fig. 3](#f3-mmr-17-01-0852){ref-type="fig"}).

### Quantification of miR-16 and miR-223

The expression levels of miR-16 and miR-223 were determined using RT-qPCR to validate the miRNA array data. The mean ΔCq ± standard deviation of miR-16 was 3.6±1.1 and 3.2±1.4 for the control and MSA groups, respectively ([Fig. 4A](#f4-mmr-17-01-0852){ref-type="fig"}). Similarly, for miR-223, the value was 2.3±1.1 and 2.0±1.4 for the control and MSA groups ([Fig. 4B](#f4-mmr-17-01-0852){ref-type="fig"}). There were no significant differences between the miRNA levels of the patients with MSA and the healthy controls.

### Quantification of IGF-1

Mean serum IGF-1 levels were revealed to be 68.1±34.2 ng/ml in control group and 105±42.1 ng/ml in the MSA group ([Fig. 4C](#f4-mmr-17-01-0852){ref-type="fig"}). However, no statistically significant difference in IGF-1 levels was detected between patients with MSA and healthy controls.

Discussion
==========

In the present study, 50 upregulated miRNAs and 17 downregulated miRNAs were identified in serum from patients with MSA, using a microarray platform. The hierarchical clustering analysis identified marked differences between the miRNA profiles of the MSA and the control groups.

There are few reports on miRNA profiling in patients with MSA ([@b14-mmr-17-01-0852],[@b15-mmr-17-01-0852]). It has been demonstrated that miR-24, miR-223 and miR-324-3p are upregulated in the serum of patients with MSA or PD ([@b14-mmr-17-01-0852]), and a greater upregulation of miR-24, miR-34b and miR-148b was observed in MSA when compared with PD. In studies investigating miRNA in the MSA brain, it was observed that miR-96 was upregulated in the frontal cortex ([@b16-mmr-17-01-0852]) and miR-202 was upregulated in the cerebellum ([@b15-mmr-17-01-0852]).

The results of the present study also identified that miR-24 and miR-223 were upregulated in MSA serum, as described previously ([@b14-mmr-17-01-0852]). These results indicate that the methods used by the present study to determine the profile of miRNA are valid. However, the upregulation of miR-96 and miR-202 described in these previous studies in MSA brain tissue was not observed in the present study. These differing results may be due to the differences between the brain tissue and serum samples used in each study.

A previous study demonstrated that the expression of several miRNAs was altered in a mouse model of pre-motor stage MSA ([@b17-mmr-17-01-0852]) however, in the present study, this altered expression of miRNA was not observed. These differing results may be due to differences between mouse brain tissue and human serum.

miR-16 was the most elevated miRNA in the present study. The function of miR-16 has been primarily investigated in the field of oncology, and has been demonstrated to act as a tumor suppressor, an oncomiR (an miRNA associated with cancer), a modulator of the immune response and a negative regulator of angiogenesis ([@b18-mmr-17-01-0852]). It has also been reported that miR-16 promotes α-synuclein aggregation by downregulating heat shock protein 70 (HSP70) in a neuroblastoma cell line ([@b19-mmr-17-01-0852]). A previous study of brain tissue with MSA identified that the dysfunction of HSP70 may contribute to neuronal cell death ([@b20-mmr-17-01-0852]). Therefore, the elevation of miR-16 in the serum of patients with MSA may cause an accumulation of α-synuclein via the downregulation of HSP70, which may be associated with the pathogenesis of MSA.

Previous studies have demonstrated that miR-24 ([@b21-mmr-17-01-0852]), and the other upregulated miRNAs identified in the present study \[miR-17 ([@b22-mmr-17-01-0852]), miR-20a ([@b23-mmr-17-01-0852],[@b24-mmr-17-01-0852]), miR-25 ([@b25-mmr-17-01-0852]), miR-30d ([@b26-mmr-17-01-0852],[@b27-mmr-17-01-0852]) and miR-451 ([@b28-mmr-17-01-0852])\], are associated with autophagy. These miRNAs serve a role in inhibiting autophagy, downregulating the expression of target genes ([Table IV](#tIV-mmr-17-01-0852){ref-type="table"}). In brain tissue with MSA, an impairment of autophagy has been observed ([@b29-mmr-17-01-0852]). These miRNAs may decrease the level of autophagy-associated protein and induce the impairment of autophagy in patients with MSA.

In agreement with a previous study, miR-223 was also upregulated in the present study ([@b14-mmr-17-01-0852]). It has been demonstrated that upregulation of miR-223 is associated with the pathophysiology of infection, inflammation and cancer ([@b30-mmr-17-01-0852]). An *in vitro* study indicated that miR-223 downregulated the IGF-1 receptor and inhibited cell proliferation ([@b10-mmr-17-01-0852]). In addition, the serum IGF-1 level increased in patients with MSA and is associated with disease progression ([@b9-mmr-17-01-0852]). Therefore, an upregulation of miR-223 expression may contribute to the inhibition of IGF-1 signaling and thus induce cell death. Elevated IGF-1 levels in patients with MSA may be a compensatory response to upregulated miR-223. The present study assessed serum IGF-1 levels by the immune radio metric assay and serum miR-223 levels were measured by RT-qPCR. However, there were no significant differences observed between the IGF-1 and miR-223 levels in patients with MSA and the healthy controls in the present study; these results may be due to the small sample size.

The present study also observed that members of the let-7 family were upregulated in the serum of patients with MSA. The human let-7 family, which contains 13 members, is widely recognized as a class of miRNAs that have a tumor-suppressing effect ([@b31-mmr-17-01-0852]). A previous study demonstrated that extracellular let-7b induced neurodegeneration through the neuronal toll-like receptor 7 and that the levels of cerebrospinal fluid let-7b expression in patients with Alzheimer\'s disease were higher than those observed in the healthy control subjects ([@b32-mmr-17-01-0852]). Similarly, let-7 family members, including let-7b, may induce neurodegeneration in patients with MSA.

Using a microarray platform, the present study identified 22 upregulated miRNAs and 17 downregulated miRNAs in the serum of patients with MSA-P. The hierarchical clustering analysis observed marked differences in the miRNA profiles between the MSA and control groups. These alterations in the expression of miRNA may explain the differences between the pathophysiology of patients with MSA-P and MSA-C.

The present study had a number of limitations. The sample size was small and no validation of the level of miRNA expression was performed. In future investigations, a greater number of patients with MSA should be examined and individual miRNA expression levels should be determined by RT-qPCR. In addition, the present study analyzed serum miRNA, not cerebrospinal fluid (CSF) miRNA, the latter of which may be more appropriate for investigating neurodegenerative disorders such as MSA. However, analyses of miRNA expression in the serum of individuals with MSA may be more suitable, as obtaining serum samples is easier than collecting CSF samples.

In conclusion, the present study identified dysregulated miRNAs in the serum of patients with MSA. These miRNAs may serve as effective biomarkers for MSA and contribute to the pathogenesis of MSA, which may involve the accumulation of α-synuclein and the suppression of autophagy.

![Quality of total RNA and miRNA expression in the serum of a typical patient with MSA. (A) The bands of 18S (arrow) and 28S (arrowhead) ribosomal RNA in the gel were detected using a 2100 Bioanalyzer. (B) Representative miRNA expression in control and MSA cases, using miRNA chip analysis. Spot numbers 1 to 11 are presented: 1, miR-16; 2, miR-223; 3, miR-25; 4, let-7c; 5, miR-17; 6, let-7d; 7, let-7i; 8, let-7b; 9, miR-24; 10, let-7a; 11, miR-20a. MSA, multiple system atrophy; miRNA/miR, microRNA.](MMR-17-01-0852-g00){#f1-mmr-17-01-0852}

![Hierarchical clustering of miRNAs from the healthy controls and patients with MSA. Samples are arranged in columns and miRNAs in rows. The miRNA clustering tree is presented on the left, and the sample clustering tree is present at the top of each heat map. Heat maps depict the relative expression intensity for each miRNA in which the base-2 logarithm of the intensity is median-centered for each row. The color coding is indicated as a horizontal bar. MSA, multiple system atrophy; miRNA, microRNA.](MMR-17-01-0852-g01){#f2-mmr-17-01-0852}

![Hierarchical clustering of miRNAs from the MSA-P and MSA-C patients. Samples are arranged in columns and miRNAs in rows. The miRNA clustering tree is shown on the left, and the sample clustering tree is shown at the top of each heat map. Heat maps depict the relative expression intensity for each miRNA in which the base-2 logarithm of the intensity is median-centered for each row. The color coding is indicated as a horizontal bar. MSA, multiple system atrophy; MSA-P, parkinsonian MSA; MSA-C, cerebellar MSA; miRNA, microRNA.](MMR-17-01-0852-g02){#f3-mmr-17-01-0852}

![Expression levels of miR-16 and miR-223, and IGF-1 concentration in the serum of healthy controls and patients with MSA. Expression levels of (a) mir-16 and (b) mir-223 were compared between the controls and patients with MSA. (c) Serum IGF-1 concentration was compared between the controls and patients with MSA. Statistical significance was evaluated using unpaired Student\'s t-test. n.s, not significant; miR, microRNA; IGF-1, insulin-like growth factor-1; MSA, multiple system atrophy.](MMR-17-01-0852-g03){#f4-mmr-17-01-0852}

###### 

Profiles of patients with MSA-P and -C.

  Patient number   Age (years)   Sex   Subtype   Diagnostic criteria   Disease duration (years)
  ---------------- ------------- ----- --------- --------------------- --------------------------
    1              59            M     P         Possible              3
    2              64            M     C         Probable              5
    3              69            M     C         Possible              3
    4              64            M     C         Probable              7
    5              63            M     P         Definite              8
    6              75            F     P         Probable              9
    7              62            F     C         Probable              10
    8              66            M     P         Probable              3
    9              69            M     C         Possible              5
  10               49            F     P         Possible              2

Diagnostic criteria, all of the patients with MSA were diagnosed according to the 2008 consensus statement on the diagnosis of MSA ([@b8-mmr-17-01-0852]). MSA, multiple system atrophy; P, parkinsonian form of MSA; C, cerebellar form of MSA; M, male; F, female.

###### 

Statistical results and chromosomal locations of miRNAs in the 10 patients with MSA and 6 healthy controls.

  miRNA                Fold change (MSA/control)   P-value   Chromosomal localization
  -------------------- --------------------------- --------- --------------------------
  Upregulated                                                
    hsa-miR-16         4.42                        0.009     13q14.2
    hsa-miR-451        4.21                        0.017     17q11.2
    hsa-miR-103a       3.43                        0.006     5q34
    hsa-miR-223        3.28                        0.007     Xq12
    hsa-miR-486-5p     2.70                        0.023     8p11.21
    hsa-miR-107        2.45                        0.014     10q23.31
    hsa-miR-25         2.42                        0.029     7q22.1
    hsa-miR-3135b      2.31                        0.035     6
    hsa-miR-15b        2.19                        0.009     3q25.33
    hsa-miR-185        2.14                        0.010     22q11.21
    hsa-miR-939        2.09                        0.048     8q24.3
    hsa-miR-92a        2.08                        0.036     13q31.3
    hsa-miR-4298       2.07                        0.006     11
    hsa-miR-92b        2.07                        0.019     1q22
    hsa-let-7c         2.02                        0.006     21q21.1
    hsa-miR-17         1.97                        0.007     13q31.3
    hsa-miR-4693-3p    1.95                        0.005     11
    hsa-miR-130a       1.95                        0.010     5q34
    hsa-let-7d         1.91                        0.012     9q22.32
    hsa-let-7i         1.91                        0.003     12q14.1
    hsa-miR-484        1.90                        0.004     16p13.11
    hsa-miR-4791       1.89                        0.019     3
    hsa-miR-522        1.88                        0.003     19q13.42
    hsa-miR-26a        1.88                        0.033     3p22.2
    hsa-let-7b         1.86                        0.024     22q13.31
    hsa-miR-3605-3p    1.86                        0.009     1
    hsa-miR-30d        1.83                        0.006     8q24.22
    hsa-miR-4434       1.80                        0.016     2
    hsa-miR-4281       1.80                        0.007     5
    hsa-miR-106a       1.76                        0.015     Xq26.2
    hsa-miR-3667-3p    1.74                        0.008     22
    hsa-miR-99a        1.74                        0.040     21q21.1
    hsa-miR-24         1.74                        0.017     9q22.32
    hsa-miR-221        1.73                        0.020     Xp11.3
    hsa-miR-31         1.73                        0.024     9p21.3
    hsa-miR-1285       1.73                        0.007     7q21-q22
    hsa-miR-218-2      1.70                        0.041     5q34
    hsa-let-7a         1.70                        0.025     9q22.32
    hsa-miR-27a        1.68                        0.019     19p13.13
    hsa-miR-20a        1.68                        0.015     13q31.3
    hsa-miR-518a-3p    1.67                        0.043     19q13.42
    hsa-miR-19b        1.67                        0.028     13q31.3
    hsa-miR-10b        1.67                        0.028     2q31.1
    hsa-miR-377        1.66                        0.015     14q32.31
    hsa-miR-4698       1.65                        0.033     12
    hsa-miR-186        1.65                        0.042     1p31.1
    hsa-miR-126        1.64                        0.032     9q34.3
    hsa-miR-1303       1.61                        0.032     5
    hsa-miR-500b       1.61                        0.029     Xp11.23
    hsa-miR-3622a-5p   1.61                        0.002     8
    hsa-miR-3139       0.50                        0.037     4
  Downregulated                                              
    hsa-miR-4325       0.46                        0.0003    20
    hsa-miR-380        0.50                        0.0008    14q32.31
    hsa-miR-3912       0.51                        0.0019    5
    hsa-miR-4661-3p    0.54                        0.0032    8
    hsa-miR-4795-3p    0.55                        0.0038    3
    hsa-miR-4458       0.55                        0.041     5p15.31
    hsa-miR-3155       0.55                        0.0082    10
    hsa-miR-590-3p     0.55                        0.045     7q11.23
    hsa-miR-147b       0.56                        0.0034    15q21.1
    hsa-miR-4439       0.56                        0.046     2
    hsa-miR-378i       0.56                        0.016     22
    hsa-miR-3939       0.57                        0.0058    6
    hsa-miR-4495       0.58                        0.026     12
    hsa-miR-526b       0.58                        0.036     19q13.42
    hsa-miR-548z       0.58                        0.041     12
    hsa-miR-3183       0.59                        0.0082    17

miRNA/miR, microRNA; MSA, multiple system atrophy; hsa, human (*Homo sapiens*).

###### 

Statistical results and chromosomal locations of miRNAs in the patients with MSA-P and -C.

  miRNA               Fold change (MSA-P/-C)   P-value   Chromosomal localization
  ------------------- ------------------------ --------- --------------------------
  Upregulated                                            
    hsa-miR-4790-3p   3                        0.0016    3p26.1
    hsa-miR-3919      2.31                     0.015     3q25.32
    hsa-miR-4436a     2                        0.025     2p11.2
    hsa-miR-3202      1.97                     0.027     Xq28
    hsa-miR-4450      1.95                     0.0014    4q21.1
    hsa-miR-4771      1.9                      0.032     2p11.2
    hsa-miR-331-3p    1.89                     0.021     12q22
    hsa-miR-3064-3p   1.87                     0.033     17q23.3
    hsa-miR-4751      1.87                     0.019     19q13.33
    hsa-miR-617       1.82                     0.03      12q21.31
    hsa-miR-4470      1.8                      0.014     8q12.3
    hsa-miR-4755-3p   1.76                     0.045     20q11.22
    hsa-miR-379       1.75                     0.048     14q32.31
    hsa-miR-3714      1.7                      0.001     3p24.3
    hsa-miR-4506      1.69                     0.0032    14q32.12
    hsa-miR-454       1.68                     0.035     17q22
    hsa-miR-135a      1.66                     0.038     3p21.2
    hsa-miR-652       1.61                     0.007     Xq23
    hsa-miR-4790-3p   3                        0.0016    3p26.1
    hsa-miR-3919      2.31                     0.015     3q25.32
    hsa-miR-4436a     2                        0.025     2p11.2
    hsa-miR-3202      1.97                     0.027     Xq28
  Downregulated                                          
    hsa-miR-518f      0.37                     0.041     19q13.42
    hsa-miR-4703-5p   0.41                     0.043     13q14.3
    hsa-miR-3189-3p   0.44                     0.008     19p13.11
    hsa-miR-655       0.46                     0.017     14q32.31
    hsa-miR-3168      0.5                      0.015     13q14.11
    hsa-miR-105       0.51                     0.014     Xq28
    hsa-miR-1294      0.53                     0.011     5q33.2
    hsa-miR-3686      0.53                     0.019     8q24.21
    hsa-miR-4330      0.53                     0.012     Xq28
    hsa-miR-508-5p    0.53                     0.014     Xq27.3
    hsa-miR-3591-3p   0.53                     0.027     18q21.31
    hsa-miR-298       0.54                     0.042     20q13.32
    hsa-miR-3682-5p   0.54                     0.032     2p16.2
    hsa-miR-3115      0.55                     0.046     1p36.12
    hsa-miR-3192      0.55                     0.035     20p11.23
    hsa-miR-3975      0.55                     0.037     18q12.2
    hsa-miR-518f      0.37                     0.041     19q13.42

miRNA/miR, microRNA; MSA, multiple system atrophy; P, parkinsonian form of MSA; C, cerebellar form of MSA; hsa, human (*Homo sapiens*).

###### 

miRNAs and target genes associated with autophagy.

  Author, year                                                     miRNA     Target gene                           (Refs.)
  ---------------------------------------------------------------- --------- ------------------------------------- ---------------------------------------------------------------------
  Kawamoto *et al*, 2007                                           miR-24    ATG4                                  ([@b20-mmr-17-01-0852])
  Pan *et al*, 2015                                                miR-17    ATG7                                  ([@b21-mmr-17-01-0852])
  Comincini *et al*, 2013; Sun *et al*, 2015; Wang *et al*, 2015   miR-20a   ULK1, LC3-II, ATG16L1                 ([@b22-mmr-17-01-0852],[@b23-mmr-17-01-0852],[@b25-mmr-17-01-0852])
  Wu *et al*, 2012                                                 miR-25    ULK1                                  ([@b24-mmr-17-01-0852])
  Wang *et al*, 2015; Yang *et al*, 2013                           miR-30d   Beclin-1, BNIP3L, ATG2, ATG5, ATG12   ([@b25-mmr-17-01-0852],[@b26-mmr-17-01-0852])
  Zhang *et al*, 2014                                              miR-451   TSC1                                  ([@b27-mmr-17-01-0852])

miRNA/miR, microRNA; ATG, autophagy-related; ULK, Unc-51 like autophagy activating kinase; LC3, microtubule-associated protein 1A/1B-light chain 3; BNIP3L, BCL2 interacting protein 3 like; TSC1, tuberous sclerosis 1.
